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ABSTRACT
The various sphingosine kinase (SphK) isoenzymes (isozymes) and isoforms, 
key players in normal cellular physiology, are strongly implicated in cancer and 
other diseases. Mutations in SphKs, that may justify abnormal physiological function, 
have not been recorded. Nonetheless, there is a large and growing body of evidence 
demonstrating the contribution of gain or loss of function and the imbalance in the 
SphK/S1P rheostat to a plethora of pathological conditions including cancer, diabetes 
and inflammatory diseases. SphK is expressed as two isozymes SphK1 and SphK2, 
transcribed from genes located on different chromosomes and both isozymes catalyze 
the phosphorylation of sphingosine to S1P. Expression of each SphK isozyme produces 
alternately spliced isoforms. In recent years the importance of the contribution 
of SpK1 expression to treatment resistance in cancer has been highlighted and, 
additionally, differences in treatment outcome appear to also be dependent upon SphK 
isoform expression. This review focuses on an exciting emerging area of research 
involving SphKs functions, expression and subcellular localization, highlighting the 
complexity of targeting SphK in cancer and also comorbid diseases. This review also 
covers the SphK isoenzymes and isoforms from a historical perspective, from their 
first discovery in murine species and then in humans, their role(s) in normal cellular 
function and in disease processes, to advancement of SphK as an oncotarget.
INTRODUCTION
Sphingosine kinase (SphK), categorized as 
a bioactive lipid enzyme, is a central player in the 
sphingolipid rheostat [1-5]. The sphingolipid rheostat was 
first coined in the mid-nineties to describe the repression 
of ceramide-mediated programmed cell death through 
the conversion of sphingosine, a metabolite of ceramide, 
to sphingosine-1-phosphate (S1P) [5-7]. In this role, 
SphK modulates the balance between S1P, sphingosine 
and ceramides to maintain physiological levels of 
sphingosine and ceramide [8-10]. Activity of SphK/S1P 
is enhanced through cytokines, hormones, and growth 
factor stimulation [10-14]. Thus SphK is the rate-limiting 
enzyme that maintains the level of S1P for cell survival 
and normal cell proliferation and function. Conversely, 
S1P is enzymatically degraded by S1P lyase to maintain 
the level of S1P at normal physiological levels (Figure 
1) [8, 15]. As will be described in this review, SphK has 
two major isoenzymes (isozymes), SphK1 and SphK2, 
and each isozyme is expressed as a number of isoforms 
[16-18]. Differences in conformation and dimerization 
properties, in addition to the varying subcellular 
localizations of SphK isozymes and isoforms, contribute 
to the diversity in SphK functions. SphK isozymes have 
some redundancy and compensatory functions in “normal” 
physiology, as described in mouse models. SphK knockout 
mice with deletion of either isozyme show no obvious 
phenotypic abnormalities [19-21]. Deletion of both 
isozymes results in embryonic fatality [19]. 
Recently our attention has been drawn to the 
diversity in biological functions of the SphK1 and SphK2 
isoforms whereby each isozyme has multiple isoforms 
differing only at the N-terminus [16, 22-24]. There is a 
strong suggestion that imbalances of SphK1 isoform 
abundance may play a crucial role in the pathophysiology 
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of diverse diseases, may contribute to resistance to 
current anti-cancer drug therapies [25-27], and may have 
consequences for therapies targeting SphK1 and S1P in 
the presence of comorbid conditions [15, 28]. Importantly, 
emerging evidence suggests that although high expression 
of both SphK-1a and -1b isoforms are associated with 
oncogenicity, the aberrant expression of the isoforms may 
be important to the efficacy of anti-SphK1 drug therapies 
[25, 26, 28]. Thus SphK isoform function and role in 
normal physiology and disease initiation and progression 
certainly merit further examination. This review updates 
our current knowledge of the SphK isozymes and 
highlights recent findings on the two prominent isoforms, 
SphK1a and SphK1b, and potential implications for 
efficacy of SphK1 directed cancer drug administration 
and outcome.
CELLULAR PHYSIOLOGICAL ROLES 
OF SPHK, S1P AND S1P RECEPTORS 
(S1PR)
The evolutionary conservation of SphK amino 
acid sequences from protozoa, zebrafish and mammals 
(illustrated in Supplementary Figure 1) and its ubiquitous 
presence in living tissues highlights the importance of 
the cellular signaling pathway mediated by SphK [10]. 
It is therefore undeniable that SphK/S1P signaling is 
indispensable for healthy cell maintenance [29]. One of 
the main functions across all species is the role of S1P 
as an intracellular second messenger regulating calcium 
mobilization, balancing cell growth and survival [10]. 
In mammals, SphK/S1P is pivotal for normal 
cellular physiology through roles in cell proliferation, 
survival, differentiation, motility and intracellular 
calcium regulation [30, 31]. SphK activation of S1P is 
critical for embryonic development including, directed 
cell movement, organogenesis, cardiac development, 
maturation of vasculature, cellular immunity, and 
protection against apoptosis [10, 32]. S1P signaling is 
also essential for neurogenesis, lymphocyte trafficking 
and vascular development [33, 34]. Ongoing diverse 
roles for SphK/S1P in cellular maintenance also include 
protecting the heart and brain from ischemic damage 
[35, 36], protecting mitochondrial function [35, 37], 
regulating insulin synthesis, muscle insulin resistance, 
reduced glucose levels, maintenance of blood vessels and 
decreasing inflammation [15]. 
SphK promotes S1P activation through the dual 
intra- and extra- cellular actions of S1P, referred to as the 
“inside-out” signaling of S1P [38, 39]. Extracellular S1P 
acts as a primary messenger, or ligand receptor, whereby 
its signaling is modulated through binding to one of 
five-cell surface S1P receptors (S1PR1-5), also referred 
to as S1P-specific G protein-coupled transmembrane 
receptors (GPCRs), and endothelial differentiation gene 
(EDG)  receptors [30, 31, 40, 41]. Regulation of S1P 
signaling through these five G-protein coupled-receptors is 
important for normal development and vascular maturation 
[31, 41]. This family of S1PRs are differentially regulated 
in different cell types to exert different cellular responses to 
S1P activation. The S1P1-3 receptors are widely distributed 
Figure 1: The sphingosine kinase (SphK) rheostat in the maintenance of cell proliferation and function. SphK is a 
phospholipid enzyme that converts sphingosine to S1P. Through the repression of sphingosine by phosphorylation, SphK modulates the 
balance between S1P and sphingosine and ceramides to promote cell survival, normal cell proliferation and cell function. SphK has intrinsic 
catalytic activity to facilitate a housekeeping role in maintaining physiological levels of sphingosine and ceramide and is also stimulated 
by mitogens such as growth factors, estradiol, and ERK. On the other hand, S1P lyase irreversibly degrades S1P into hexadecenal and 
phosphoethanolamine while S1P phosphatase dephosphorylates S1P to sphingosine to maintain physiological levels of S1P and maintain 
homeostasis. 
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whereas S1PR4 is expressed in lymphoid tissues and lung, 
and S1PR5 expression is restricted to the nervous tissue, 
each receptor having distinct, and overlapping intracellular 
signaling pathways [41]. Not all the S1PRs are expressed 
on cells at the same time, and may be differentially 
expressed depending on stage of maturation and activation 
of the cell [31]. In mouse models, S1PR1 is essential for 
embryonic vascular development [34], whereas S1PR2 and 
S1PR3 show no obvious phenotypic differences [42]. In 
addition to extracellular S1P acting through S1PRs, S1P 
can function independently of S1PRs inside the cell as a 
second messenger. As reviewed by Strub and colleagues 
[43] the type of SphK isozyme and the location within the 
cell are responsible for the ‘inside-out’ signaling of S1P in 
response to extracellular stimuli. 
In summary, the activation and response to S1P 
varies in a cell- or tissue- specific manner resulting 
from the SphK isozyme expression, sub-compartment 
localization of these enzymes, and the differential 
expression of the S1P receptors. The importance of these 
specific interactions in cancer transformation will be 
discussed. 
SPHINGOSINE KINASE ISOENZYMES 
(ISOZYMES)
Previous studies have identified two SphK isozymes, 
SphK1 (SK1, SPK1) and SphK2 (SK2, SPK2), each with 
the ability to catalyze the phosphorylation of sphingosine 
to its pro-active form S1P [16, 22-24]. Both SphKs 
isozymes act through the same substrate, sphingosine, and 
exert intra- and extracellular actions through their ability to 
phosphorylate sphingosine to S1P [10]. The two isozymes 
have different tissue distribution with SphK1 being highly 
expressed in spleen, lung and leukocytes and SphK2 being 
highly expressed in liver and kidney [16]. SphK2 also 
appears much later in embryologic development compared 
to SphK1 [16]. As shown in murine models, knockout 
of both SphK isozymes is lethal, leading to embryonic 
fatality and SphK deficient mice present with defects in 
neural and vascular development [19]. 
The two isozymes are expressed from different 
chromosome locations: the gene encoding the SphK1 
isozyme is located on chromosome 17 (17q25.2) 
and the gene encoding the SphK2 isozyme maps to 
chromosome 19 (19q13.2) [16]. The SphK2a and SphK1a 
isozymes, differ considerably in size (618 amino acids 
Table 1: Involvement of hSphK in the pathogenesis of cancer and other diseases










Colon [80, 81, 122]
Gastric [123]
Liver and bile ducts [124, 125]





Alzheimer’s disease [142, 144-154]
Amyotrophic lateral sclerosis (ALS) [155]
Dementia [156]
Diabetes [76, 157-175]
Inflammatory diseases Asthma, Atherosclerosis, Inflammatory bowel disease, Edema Autoimmune disorders such as 





*This is not an exhaustive list of SphK references but includes the most relevant studies for each disease type.
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in length compared to 384 amino acids respectively) 
but, nonetheless, retain 45% overall identity and 80% 
similarity with comparable enzymic activity [16]. 
Although the two SphK isozyme protein sequences 
differ, they share five conserved domains involved in ATP 
binding and catalytic conversion of sphingosine to S1P 
[44, 45]. The size difference between the two isozymes 
result from additional amino acids in the N-terminal 
region, and a unique central proline-rich region which 
appears to coincide with the sphingosine binding region 
[46]. Studies of this SphK2 unique proline-rich region 
suggest it may confer some promiscuity to this isozyme in 
context of substrates it can phosphorylate [46]. This unique 
N-terminal region also allows for the targeting of isozyme 
selective inhibitors. Differences in the sphingosine binding 
region between the two SphK isozymes also allow SphK1 
and SphK2 selective ATP competitive inhibitors to be 
developed therefore permitting isozyme-specific inhibitory 
therapeutic targeting [47]. SphK2 also contains a nine 
amino acid domain similar to the pro-apoptotic BH3 
Table 2: SphK inhibitors 
SphK inhibitor SphK selectivity References
SKi (2-(p-hydroxyanilino)- 4-(p-chlorophenyl)thiazole) or SK1-II   SphK1 and SphK2 [18, 47, 239]
Safingol SphK1 and SphK2 [283]
L-threo-dihydrosphingosine (DHS) SphK1 and SphK2 [284]
N,N-dimethyl-D-erythro-sphingosine (DMS) SphK1 and SphK2 [18]
B‐5354c, F-12509A (Natural products) SphK1 and SphK2 [18]
ABC294735 SphK1 and SphK2 [47]
Amgen 82 SphK1 and SphK2 [276]
Amidine-based range of sphingosine analogues SphK1 and SphK2 [18]
MP-A08 SphK1 and SphK2 [271]
ST-1083 SphK1 and SphK2 [285]
S-15183a and S-15183b 
(Natural product) Not specified
[18]
PF-543 ((R)-(1-(4-((3-methyl-5-(phenylsulfonylmethyl)phenoxy) 
methyl)benzyl)pyrrolidin-2-yl)methanol), SK1-5c  (CAY10621), 






SKI-I SphK1 [97, 289, 290]
LCL351 SphK1 [291] 
Compound inhibitors 51 and 54 SphK1 [271, 292]
Balanocarpol SphK1 [293]
VPC94075 SphK1 [294] 
1-deoxysphinganines 55-21 and 77-7




(S)-FTY720 vinylphosphonate SphK1 [297]
Genzyme SphK1 [27, 276]
ABC294640 SphK2 [18, 298]
SG-12  and SG14 (sphingosine analog) SphK2 [299]
SLC5111312 and SLM6041434 SphK2 [300]
F02 thiourea adduct of sphinganine SphK2 [295]
VT-ME6 SphK2 [301]
(2S,3S,4R)-Pachastrissamine SphK2 [302]
Trans-12a and Trans 12b SphK2 [301]




domain (Bcl2 homology domain 3), which is believed to 
be involved in the control of calcium levels in the cell, and 
in some culture conditions such as serum starvation [22]. 
Initial studies in SphK1 and SphK2 knockout mouse 
models describe opposing functions of overexpression 
of mSphK2 and mSphK1 isozymes, SphK1 is linked 
with pro-survival and cell maintenance functions, 
whereas SphK2, in contrast, has been linked with cell 
growth inhibition and enhanced cellular apoptosis [22]. 
Interestingly, this simplistic viewpoint has shifted [46] and 
recent emerging functions of SphK1 and SphK2, relevant 
to the newly emerging SphK-targeting cancer therapies, 
will be discussed. The different biological functions of 
the two SphK isozymes have been attributed to differing 
temporal and spatial regulation through post-translational 
modification and specific protein and lipid interactions 
[46], which allows for localized S1P production and 
provides downstream targets within the cell [22, 48]. 
This distinct intracellular sub-compartmentalization has 
been cited as the driving force underpinning their diverse 
biochemical roles ( [48] and references therein). SphK1 
is located mainly in the cytoplasm and the cell membrane 
whereas SphK2 is mainly located in the mitochondria, 
nucleus, and the endoplasmic reticulum (ER) (Figure 
2) [37, 48-50]. Overexpression of SphK2 increases 
cytosolic free calcium, inducing apoptosis, which is partly 
attributed to the unique SphK2-specific pro-apoptotic 
BH3 domain, not present in SphK1 [22]. Established 
functional roles for SphK1 in actin remodeling, 
endocytic recycling and endocytic membrane trafficking 
to maintain plasma membrane homeostasis have been 
described [51]. Furthermore, SphK1 has an important 
role in neurotransmission and is highly enriched in nerve 
terminals, specialized subcellular compartments of exo-
endocytosis [51].
Interestingly, despite the distinct properties and 
Figure 2: Subcellular distribution of SphK isozymes and function. A. SphK is expressed as two isozymes designated 
SphK1 and SphK2. Each SphK isozyme has variant isoforms differing only at the N-terminus. B. The distinct functions of hSphK1 
and hSphK2 isozymes are believed to be associated with subcellular localization. SphK2 isoforms are predominantly localized in the 
nucleus, mitochondria, and endoplasmic reticulum (ER) and produce S1P. While located at the ER, SphK phosphorylates sphingosine to 
S1P, conversely, S1P phosphatase removes the phosphate and S1P lyase degrades S1P to induce apoptosis. In the mitochondria, Sphk2 
catalysis to produce S1P triggers the apoptotic pathway by activating BAK and Cyt C. Conversely, hSphK1 is predominantly located in the 
cytoplasm and translocates to the membrane upon activation. Upon activation, hSphK1a/b/c phosphorylates sphingosine to produce S1P 
and has an “inside/outside” mechanism whereby S1P is translocated outside the cell and can bind to S1P1-5 receptors (also referred to as 
G-coupled receptors) contributing mainly to cell survival. HSphK1 isoforms have also been found extracellular. In mice, SphK1 isoform 
b has been shown to be located to the plasma membrane and more susceptible to degradation, however, to-date, no distinction between 
hSphK1 isoform localization has been demonstrated in the different human cells and human tissue with the exception that hSphK1a has 
been shown to be distributed in the nucleus and cytoplasm in cell culture. Fig 2B has been adapted from [27].
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locations of SphK1 and SphK2 within the cell and mice 
with deletion of both isozymes is embryologically lethal, 
mice with deletion of either isozyme show no obvious 
abnormalities at birth, remain viable, have no obvious 
differences in longevity, and histological analysis reveals 
no major abnormalities of organ structure, [19, 52], and 
Table 3: Comparative selectively of the S1P modulators 
S1P modulator S1PR selectivity References
Agonists
FTY720* S1P1>S1P5>S1P4>S1P3 [110]
Fingolimod* and phosphorylated 
fingolimod
(Trade name: Gilenya)
S1PR1, S1PR3, S1PR4, S1PR5 [234, 304-308]
S1P-specific antibody Depletion of S1P [18]
CS-0777* S1P1>S1P5>S1P3 [309]
Ponesimod (ACT-128800) S1P1>S1P5>S1P3 [271]
RPC0163* S1P1>S1P5>S1P3>S1P2 [271]
ONO-4641 S1P1>S1P5>S1P4 [310, 311]
Siponimod (BAF312) S1P1>S1P5>S1P4 [312]
GSK2018682 S1P1>S1P5 [271]
SEW2871 S1P1 [313, 314] 
AUY954 S1P1 [315, 316]   
MT-1303 S1P1 [271]
KRP-203 and phosphorylated KRP-203 S1P1>S1P4 [317, 318]
AAL(R) and phosphorylated AAL(R)
(FTY720 analogue)
S1PR1, S1PR3, S1PR4, S1PR5 [294, 319, 320]
CYM-5442 S1P1 [321, 322]
VPC23153 S1P4 [323, 324] 
W-061 S1P1> S1P5> S1P4> S1P3
[310, 325] 










W146 S1P1 [329, 330]
JTE-013 S1P2 [189, 331]
NIBR-0213 S1P1 [329]
Note: *S1P modulators can act as functional antagonists. 
More detailed reviews [15, 18, 56, 57, 332].  
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SphK1 knockout mice exhibit normal inflammatory 
response [20, 53], suggesting that there is some 
redundancy in SphK1 and SphK2 functions in “normal” 
physiology, and also indicates compensatory functions 
for both isozymes in the cell. This “compensatory” 
mechanism, whereby SphK1 and SphK2 complement 
each other’s actions may be explained, in part, by the 
potential fluidity of the two isozymes allowing the SphKs 
isozymes to move between subcellular compartments [54, 
55]. The proposed concept suggests that this partitioning 
of the isozymes into lipid microenvironments would 
allow SphK-isozyme specific catalytic conversion of 
sphingosine to S1P and effective binding to localized S1P 
receptors otherwise not normally accessible if under strict 
subcellular compartmentalization. Despite the importance 
of SphK in normal cellular function and the strong 
association between aberrant SphK/S1P signaling and 
diseases, the mechanisms whereby lipid kinases locate and 
act on their substrates, in general, is not well understood. 
INVOLVEMENT OF SPHK AND S1P IN 
THE PATHOGENESIS OF CANCER AND 
OTHER DISEASES
As key players in normal physiology and in 
disease, it is unsurprising that there is a large body of 
evidence demonstrating the contribution of an imbalance 
in the SphK/S1P rheostat to a plethora of pathological 
conditions including cancer, diabetes, inflammatory 
diseases, neurodegenerative diseases (Parkinson’s and 
Alzheimer’s), cardiovascular and liver diseases, which 
have been extensively reviewed [2, 3, 11, 15, 18, 48, 56-
72]. Although removal of one of the major SphK isozymes 
is not fatal, as determined in mice with knockout of either 
SphK1 or SphK2, what these studies have revealed is that 
loss of one isozyme increases the risk of major health 
problems including altered vasculature formation [73, 
74], impairment in wound healing [75], abnormal islet 
formation, which could lead to type 1 diabetes [76], 
and cardiac dysfunction (ischemic) [77], among other 
complications. Alternatively, overexpression of SphK1 
and aberrations in the “inside-out” dual mechanism of 
SphK1/S1P activation have been reported as contributors 
to cancer and inflammation [38, 39, 56, 78, 79], and 
this is supported by studies in SphK1-deficient mice, 
for example, reduction of SphK1 reduced colon cancer 
development [80, 81]. 
Although initial studies focused on SphK2 as a 
pro-apoptotic protein more recent evidence describes 
dual functionality for SphK2: a protective function in cell 
Figure 3: Designer anti-S1PR1-5 drug specificity. Update of 1st and 2nd generation S1P receptor modulators developed to target 
individual and multiple S1P receptors. Each of the receptor modulators binds to individual or multiple receptors to block or activate the 
SIPRs as illustrated. MOST S1PR modulators target 2 or more receptors. Sipon (BAF312) - Siponimod is a S1P1 = 5 > 4 modulator; 
Ponesimod (ACT-128800) is an agonist for S1P1 > 5 > 3; KRP-203 is an agonist for S1P1 > 4; Ceralifimod (ONO-4641) is an agonist for 
S1P1 = 5 > 4; Ozanimod (RPC1063) is an agonist for S1P1 > 5 > 4; Cs-0777 is an agonist for S1P1 > 5 > 3; GSK2018682 is an agonist 
for S1P1 > 5. JTE-013 is a competitive antagonist specifically for S1P2. CYM50367 targets S1PR1/4 and VPC23019 targets S1PR1/3. 
Sew2871, AUY954, MT-1303, CYM-5442, W146, NIBR-0213, TAS0277308, are listed as selective S1P1 modulators. These novel S1P 
receptors and downstream signaling pathways and functions are reviewed in [15, 258, 281].
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maintenance as well as its characterized pro-apoptotic 
functions. As reported by Gaire [82], SphK2 is protective 
against neuronal ischemic injury, potentially protecting 
the junctional protein in the blood-brain barrier [36, 83-
86]. Furthermore, S1P production by SphK2 potentially 
protects dopaminergic neurons, the major source of 
dopamine, and potentially provides some protection 
against Parkinson’s disease through maintaining and 
promoting mitochondrial function [70]. Massberg and 
colleagues provide evidence demonstrating SphK2 
expression, regulates platelet aggregation and that 
deletion of SphK2 leads to reduced arterial thrombosis 
after vascular injury, suggesting SphK2 is a potentially 
important target for protection against arterial thrombosis 
[73, 74]. Knockout SphK2 mouse models also revealed the 
importance of SphK2 in cardio protection and survival of 
the heart [87, 88]. 
This review is not intended to cover, in any depth, 
the ever-growing list of disorders and/or the substantial 
evidence presented for the involvement of SphK/S1P 
in health and disease. For this information we refer the 
readers to the cited references and the seminal papers listed 
in Table 1. However, the changes that occur in the SphK/
S1P signaling pathways in normal compared to abnormal 
cells is still being unraveled and the involvement of SphK 
isozymes, isoforms, S1P and S1PR in the pathophysiology 
of cancer will be covered in more depth. 
INTRACELLULAR AND 
EXTRACELLULAR TARGETS OF S1P 
REGULATED BY SPHK1 AND SPHK2 
AND RELEVANCE TO CANCER
Validation of SphK1 and SphK2 as targets for 
anti-cancer treatment
Disruption of the sphingolipid rheostat has been well 
reported as a determinant of initiation and progression 
Figure 4: Alignment of the N-terminal amino acid sequences of the mSphK1 and hSphK1 isoforms. A. Three mSphK1 
isoforms (iso-a, iso-a2, and iso-b) have been identified to date. Iso-a has an additional 6 and 7 amino acids at the N-terminus (N’) compared 
to the mSphK1a2 and mSphK1b isoforms respectively. There is 10 amino acid overall sequence dissimilarity when comparing mSphK1a 
to mSphK1a2 and mSphK1b. MSphK1a2 differs from mSphK1b by an insertion of a valine (V) in the N’ changing the sequence MEPVE 
(iso-2a) to MEPEE (iso-b). B. Human SphK1 is expressed as 3 isoforms (a, b, and c) which have identical in sequences except for the 
N-terminus (N’). The SphK1b N’ has an additional 86 amino acids upstream of the Met start codon of SphK1a, as illustrated. SphK1c has 
an additional 14 amino acids upstream from the SphK1a start codon, which translates to a difference of 17 amino acids between the SphK1a 
isoform compared to SphK1c. Legend: * = complete amino acid sequence identity across all isoforms; : = similarity of amino acids across 
2 isoforms. Sequences aligned using CLUSTAL Omega (1.2.3) multiple sequence alignment tool.
Figure 5: Comparative alignment of human and murine SphK1 amino acid sequences. SphK1 amino acid sequence 
alignment showing similarities and differences in SphK1 sequences across human (H. sapiens), mouse (Mus musculus) and rat (R. 
norvegicus) species. Legend: * = complete amino acid sequence identity across all three species; : = similarity of amino acids across 2 
species. Sequences aligned using CLUSTAL Omega (1.2.3) multiple sequence alignment tool.
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of many cancers (Table 1) and a focus for anti-cancer 
treatments. Removal of SphK tips the balance from 
production of the pro-active lipid S1P, which is involved 
in cell proliferation, to the production of the inactive or 
less active ceramide lipid with pro-apoptotic functions 
(Figure 1). Extensive studies from mouse models and 
cancer cell lines have placed SphK1 as a target for cancer 
therapy. Studies using genetic knockdown of SphK1 and 
SphK2 in mouse colon cancer models revealed SphK1-/- 
mice were significantly protected against colon cancer 
whereas this protection was not evident in SphK2-/- mouse 
models [80]. Knockdown of SphK1 using siRNA in 
glioma and breast cancer cell models decreases S1P levels 
with an accompanying accumulation of ceramide resulting 
in increased apoptosis [134, 219]. Based on these initial 
findings SphK1 was identified as a prospective oncogenic 
target. Interestingly, hSphK2 ablation using RNA 
interference technology was shown to be more efficacious 
in inducing cell death [134, 220] validating both SphK1 
and SphK2 as targets for anti-cancer treatment. Here we 
present an overview of hSphK1 and hSphK2 isozymes and 
an alternative perception of hSphK2 as a more efficient 
target for anti-cancer therapy compared to SphK1. 
Oncogenic properties or “non-oncogenic 
addiction” of SphK1/S1P
Overexpression of SphK1 has been reported as 
a driver for many types of cancer and contributes to 
chemotherapy resistance and poor patient outcome 
(Table 1 and references therein). Xia and colleagues 
first identified the oncogenic potential of SphK1 in 2000 
[221], and evidence supporting a key role in neoplastic 
survival and growth has come from SphK1-/- mouse 
models showing reduced tumor size [222] and increased 
expression of hSphK1 has been reported in many different 
cancer types (Table 1) [97, 223]. Although SphK1 is 
now categorized as an oncogene, there is no evidence 
associating carcinogenesis with the presence of genetic 
mutations of SphK1 [224]. It has been widely suggested 
that the oncogenic properties of SphK1 are associated 
with “gain of function” through the overexpression and 
hyper-activation of S1P mediated intra- and extracellular 
signaling, or “non-oncogenic” addiction, may be 
responsible for SphK-associated pathophysiology [225]. 
Non-oncogenic addiction refers to the over reliance of 
cancer cells on the SphK1 signaling pathway for survival 
[226]. Normal cells do not usually tolerate high levels 
of SphK1 and in some cases high SphK1 in normal cells 
has been reported to have an anti-proliferative effect 
[225]. Enhanced intra-cellular signaling through SphK1/
S1P, independent of G-coupled receptors, was proposed 
as a mechanism responsible for hyper-proliferation 
and cell survival [227, 228]. However, increases in 
SphK1 and increases in SphK1 signaling mediated both 
intra and extra-cellular through a plethora of different 
molecules have been identified as participating in the 
“gain of function” leading to tumorigenesis and have 
been extensively reviewed in [18]. For example “gain of 
function” may occur through S1P stimulation of SphK1 
mediated by agonists such as, growth factors, estradiol, 
insulin, cytokines and/or extracellular signaling kinases 
(ERK) [90, 91, 225, 229]. Estrogen stimulates SphK1 
to promote breast cancer development [91, 93] and is 
also associated with breast cancer treatment resistance 
Figure 6: Comparative alignment of human and murine SphK2 amino acid sequences. SphK2 sequences have been aligned 
to show similarities and differences between the SphK2 isozyme sequences across human (H. sapiens), mouse (Mus musculus) and rat 
(R. norvegicus) species. Legend: * = complete amino acid sequence identity across all three species, : = similarity of amino acids across 2 
species. Sequences aligned using CLUSTAL Omega (1.2.3) multiple sequence alignment tool.
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[230]. SphK1 mediates insulin-like growth factor binding 
protein-3 (IGFBP-3) growth factor signaling in breast 
cells, where overexpression of IGFBP-3 is associated 
with cancer progression [14]. Proinflammatory cytokines, 
immunoglobulin receptors, small GTPases, calcium and 
protein kinase activators, are all described as mediators 
of SphK1/S1P activity [18, 135]. For example, interleukin 
1 (IL-1) stimulates SphK1 (not SphK2) in the brain 
contributing to chronic neuroinflammation and stimulation 
of malignant glial cells correlating with poor prognosis for 
patients with glioblastoma multiforme [135].
Although the overexpression of SphK1/S1P 
appears to be associated with promoting malignancy, 
it is becoming ever more evident that non-oncogenic 
addiction is also associated with aberrant localization and 
translocation of SphK1 post stimulation [231, 232]. SphK1 
is located mainly in the cytosol in unstimulated cells 
and upon stimulation by agonists SphK1 is upregulated 
and translocates to the plasma membrane. For example, 
SphK1 localized in the cytoplasm has been demonstrated 
to interact with the tumor necrosis factor-(TNF) receptor 
associated factor 2 (TRAF2), enhancing S1P activity 
associated with pro-survival cell signaling of S1P [233, 
234], although it is noted that the TNF-mediated response 
appears to be cell-type and cell context specific [235, 236]. 
It was in 2005 that Pitson and colleagues proposed that 
intra-cellular dysregulation of SphK1 phosphorylation and 
localization, rather than total increase in SphK1 levels, 
were key elements in the transformation of the malignant 
phenotype: i.e. subcellular-compartmentalization and 
translocation of SphK1 dictates cancer transformation 
[237]. All hSphK1 isoforms harbor a distinct 
phosphorylation site at Ser225, and phosphorylation 
of the SphK1-Ser225 site is important for translocation 
of SphK1 to the plasma membrane [55, 237]. Increased 
Ser225 phosphorylation of SphK1, as a direct consequence 
of extracellular ERK1/2-mediated phosphorylation at 
Ser225, was shown to enhance translocation of intra-
cellular SphK1 to the membrane. As a consequence 
SphK1 demonstrated an increase in catalytic activity and 
bioactive S1P, proposing that the pro-cancer effect, or 
SphK1-oncogenic ‘inside-outside’ signalling, was reliant 
on both Ser225-specific phosphorylation and translocation 
to the membrane [237]. SphK1/S1P extracellular activity 
has also been shown to promote oncogenicity through 
initiation of the formation of new vasculature to support 
new tumor growth. Blocking SphK1/S1P inhibited the 
formation of new vasculature and hence deprived the 
tumor of important nutrients [19, 97, 238]. 
New insights into the structure and function 
of SphK1 relating to its enzymic role in controlling 
fundamental cellular processes has been recently 
reviewed by Adam, Pyne and Pyne [48]. Although 
the crystal structure of SphK1 is not yet available, 
comparative analysis of closely related prokaryotic 
lipid kinase crystal structures identified a potential 
dimerization region in SphK1, which would confer 
structural plasticity, or conformational mobility, through 
phosphorylation and interaction with other proteins and 
phospholipids. Physiology of enzymatic regulation may 
well be dependent on the structural plasticity of SphK1 
and interactors and dysregulation of these interactions may 
contribute to disease. There is still a long way to go to 
understanding the structure and function of SphK1, and 
knowledge of the SphK1 crystal structure will allow the 
discovery of druggable allosteric sites and development of 
specific ligands to modulate SphK1 activity [48]. 
A role for SphK2/S1P in oncogenesis
Albeit historically SphK1 is the isozyme associated 
with oncogenesis, it is important to note that there is new 
evidence to strongly suggest that SphK2 is overexpressed 
in many human cancers [239] and dual pro- and anti- 
apoptotic functions of SphK2 may well be dictated 
by the cellular milieu within which the protein exists. 
Pitson and colleagues demonstrated that a relatively low 
increase in SphK2 levels (2.5 fold), compared to the 
levels in corresponding normal tissue, could potentially 
promote cell proliferation and neoplastic transformation, 
whereby in contrast, high levels of SphK2 are associated 
with pro-apoptotic signalling, predicted to be through the 
unique BH3 pro-apoptotic domain, that dominates over 
Figure 7: Predicted N-terminal sequence alignment of the hSphK2 isoforms. hSphK2 has 5 predicted isoforms differing only 
at the N-terminus as shown (iso-a, iso-b, iso-c and iso-d). The SphK2c isoform has a predicted 59 amino acid insertion in the N-terminal 
region compared to SphK2b. SphK2c has a predicted Met start site that is 36 amino acids downstream of the SphK2a (iso-a) start codon. 
SphK2d has the shortest sequence with a truncation of 86 amino acids from the SphK2a start codon. Legend: * = complete amino acid 
sequence identity across all isoforms. Sequences aligned using CLUSTAL Omega (1.2.3) multiple sequence alignment tool.
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the proliferative SphK2/S1P response [239]. On the other 
hand, Xia and colleagues showed that insulin stimulated 
phosphorylation of SphK2 in a similar time- and dose-
dependent manner compared to SphK1, led to similar 
activation of cell cycle progression and proliferation in 
MCF- 7 cells [229].
The SphK2 isozyme contains nuclear import and 
export sequences, allowing shuttling between the nucleus 
and cytoplasm [240]. In the nucleus SphK2 complexes 
with histone H3 and histone deacetylase 1 and 2 (HDAC 
1/2) producing S1P that regulates histone acetylation, as 
part of gene regulation [241]. SphK2-derived S1P also 
binds hTERT to allosterically mimic phosphorylation and 
maintain telomere integrity and stability through limiting 
proteasome degradation [242]. As telomere stabilization 
is enhanced in cancer S1P stabilization of telomeres 
potentially enhances tumor growth, however this is 
somewhat controversial to its role in apoptosis or cell 
protection against cancer [243]. In addition, FTY720, a 
competitive inhibitor of SphK2, has been shown to inhibit 
DNA synthesis and as a consequence, inhibited S1P-
stimulated actin rearrangement and reorganized the focal 
adhesion assembly in MCF-7 cells, potentially regulating 
the transition of MCF-7 cells from a stationary phenotype 
to a migratory phenotype [244]. 
Another example of SphK2 isozyme location 
influencing S1P function comes from Strub and colleagues 
who demonstrated S1P, produced by SphK2 in the 
mitochondria, specifically interacted with prohibitin 2 to 
control mitochondria respiration [37]. As genetic alteration 
and aberrant metabolism are two of the hallmarks of 
cancer, the link between overexpression of SphK2/S1P in 
the nucleus, affecting genetic gene regulation and stability, 
and SphK2/S1P altering mitochondria metabolism, may 
have consequences for cancer progression. 
In other studies using RNA interference to 
selectively ablate each of the SphK isozymes, SphK1 
ablation showed no effect on mRNA and protein levels 
of SphK2 however reduced intracellular S1P levels and 
increased ceramide (pro-apoptotic lipid), alternatively, 
SphK2 ablation increased intracellular activity of SphK1/
S1P [220]. Anti-intuitively, despite increased S1P levels 
in these experiments, reduction of SphK2 suppressed 
proliferation and migratory potential of cells more 
effectively than SphK1 ablation indicating targeting 
SphK2 may have stronger anti-cancer effects in cancer 
therapy [220]. 
As mentioned previously, there are inherent 
differences in the composition of the ATP and catalytic 
binding pockets of the two SphK isozymes, and specific 
SphK1 and SphK2 compounds have been developed 
targeting this peptide region to inhibit the catalytic activity 
of either isozyme and these are listed and referenced 
in Table 2. SphK2 specific inhibitors, such as the 
immunosuppressant drug ABC294640 and FTY720 have 
been shown to have greater or similar anticancer effects 
than compounds that target SphK1, such as CB5468139, 
or that target both isozymes, SK-II and ABC294735, 
making SphK2 inhibitors attractive compounds for anti-
cancer therapy [47]. The drug ABC294640 has been 
shown to reduce the growth of hormone resistant prostate 
cancer cells [245] and colorectal and colon cancer cell 
growth [246, 247]. Though SphK1 does phosphorylate 
FTY720, which acts as a pseudo ligand for S1P, binding 
of SphK2 is more potent having a 30-fold more ligand-
binding efficiency in humans and murine species [248]. 
The effect of FTY720 binding to SphK2 in the nucleus and 
preventing HDAC 1/2 repressor gene regulation has also 
been shown to restore ERα expression and hence restore 
tamoxifen sensitivity [249].
SphK2 also plays a role in cell migration in 
a cell specific manner. In the breast cancer cell line 
MDA-MB-453, cell migration towards the epidermal 
growth factor (EGF) was observed and this migration 
was abrogated by SphK2-specific siRNA whereas 
downregulation of SphK2 in HEK293 had no effect on 
migration [250]. Although it is not understood why SphK2 
involvement in cell migration is cell specific, especially 
as the majority of endogenous SphK2 was present in the 
plasma membranes of both HEK293 and MDA-MB-253 
cell lines and EGF did not affect obvious localization 
changes in SphK2, it may still be possible that SphK2 may 
relocate to specialized plasma membrane compartments 
and produce S1P in the vicinity of its receptors. Also 
there is some in vitro data to suggest that SphK2 can 
compromise the integrity of the endothelial cell monolayer 
[251], which may contribute to invasion and migration 
of cancer cells. The complex interaction between SphK 
and S1PR with reference to the potential role of SphK2 
in regulating metastasis is discussed in more detail in the 
following section.
As there is indisputable evidence to support SphK2 
compensatory mechanisms in the absence of SphK1 in 
‘normal’ physiology (at least in mouse models) [19], and 
the discovery of SphK2 specific inhibitors (FTY720 and 
ABC294640), acting as competitive inhibitors of SphK2 
(not SphK1), with the ability to be phosphorylated by 
SphK2 and be released from cells to act on S1P receptors, 
also suggests a wider functionality for this isozyme and its 
role in neoplasia and cancer [252, 253]. 
The growing evidence supporting a role for SphK2 
in cancer development provides sufficient precedent to 
warrant the inclusion of SphK2 as a candidate therapeutic 
target for many types of cancer.
S1PR EXPRESSION AND MALIGNANCY
There is ample evidence in the literature to suggest 
that the differential and overexpression of S1PR1-5 are 
involved in cancer progression and metastasis [123, 139, 
250, 254-256]. Differential expression of the S1PRs is 
known to occur at different stages of development, S1PR1 
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expression has been shown to be essential for embryonic 
development and normal physiological functions, 
especially in vascular maturation [34, 257], whereas 
S1PR2 and S1PR3 were reported to be redundant in this 
process [42]. In estrogen receptor positive (ER+) tumors 
high S1PR1 and S1PR3 were reported to be causally 
associated with tamoxifen resistance and poor prognosis 
[92], and in vitro, in ER+ MCF-7 breast cancer cells, the 
SphK1/S1PR3 loop promoted breast cancer progression 
and migration [94]. S1PR/S1P has been shown to be 
important for osteoclast formation, bone cells that break 
down bone tissue. A few recent studies have demonstrated 
that FTY720 binding to S1PR1 and or S1PR2 prevents 
osteoclast formation [258, 259]. By blocking osteoclast 
formation and reducing bone loss, FTY720 may indirectly 
have added benefits for advanced cancers that migrate 
to the bone and where metastasis involves considerable 
osteolysis [260]. 
Interesting, in many cancer cells a shift in S1PR 
expression is observed whereby, S1PR1 expression is lost 
or decreased and S1PR2 and/or S1PR3 are predominantly 
expressed [123, 139, 254, 255]. Moreover, within cancer 
cell sub-types, differences in S1PR expression correlate 
with the metastatic or non-metastatic cancer phenotype 
[123, 139]. Yamashita and colleagues demonstrated 
that gastric cells expressing high levels of S1PR3 and 
low levels of S1PR2 were causally correlated with the 
migratory phenotype in response to binding S1P, and in 
the same study, gastric cells expressing predominantly 
S1PR2 did not have the same chemotactic responses to 
S1P and did not migrate [123]. Specific inhibition of the 
S1PR2 receptor by JTE-013 (refer to Figure 3) abolished 
the inhibitory effects of S1P in S1PR2 expressing gastric 
cells. Similarly, in mouse melanoma cells overexpression 
of S1PR2 has been demonstrated to abolish the metastatic 
potential whereas S1PR1 aggravated metastasis [139]. 
Conversely, SphK1/S1P elevation of S1PR2 was shown 
to be associated with increased metastatic potential in the 
lung, breast [261] and brain [262], which is seemingly 
contradictory. A twist in the story and a clue to the 
seeming contradiction was the discovery of high S1PR4 
causal association with recurrence, reduced survival 
rates and metastasis in estrogen receptor negative breast 
tumors [256]. This led to the further finding that SphK2/
S1PR4 prevented nuclear translocation of S1PR2, which 
in turn, prevented tumor growth, providing support for 
sub-cellular distribution of S1PR2, which is important for 
oncogenic suppression [263]. Thus, these findings may 
partly explain the contradictory S1PR2 subtype-specific 
regulation of metastasis, suggesting SpK/S1P stimulated 
cell migration and proliferation is dependent on the cell-
specific diversity of the SphK and S1PR1-5 expression 
[123, 256, 261, 263, 264]. The S1PR sub-type, the level 
and the localization of S1PR expression is critical for 
the degree of cancer progression and contributes to the 
increasing complexity and challenges for SphK andS1PRS 
as oncotargets.
SPHK IN CANCER DRUG RESISTANCE
It comes as no surprise that the SphK pathway is 
associated with anti-cancer drug resistance given the 
overexpression and aberrant expression of SphKs, S1P, 
and S1PRs lead to cancer development and metastasis. 
Overexpression of SphKs, S1P and the S1PRs are causally 
associated with cancer drug resistance to conventional 
cancer treatments (radiotherapy, chemo- and hormone 
therapies) in many types of cancers, including breast 
[92, 230], pancreatic [265], and prostate cancers [266]. 
Cancer patients overexpressing SphK1 tend to have 
poorer survival rates [129, 223]. As discussed in this 
review, cancer cells can become dependent on the SphK1 
enzyme for survival and proliferation, termed non-
oncogenic addiction. In estrogen receptor (ER) positive 
breast cancer cells overexpression of SphK1 increases 
tamoxifen resistance and ablation of SphK1 restores 
tamoxifen sensitivity [92, 230]. S1P binding to S1PR3 
is associated with SphK1 translocation of SphK1 to the 
Table 4: SphK/S1p/S1PR drugs in clinical trial
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plasma membrane to promote tumorigenesis in ER+ 
breast cancer [94]. In ER negative breast cancer high 
tumor levels of S1PR4 and SphK1 are associated with 
poor patient prognosis [256, 267], and in HER2+ cells 
S1PR4/HER2+ signaling is associated with metastasis 
[267]. Similarly overexpression of SphK1 correlates with 
androgen independent refractory cells [105, 268]. 
The mechanism for SphK-induced drug resistance 
is unclear, however, much effort has gone into developing 
anti-SphK designer drugs to overcome drug resistance as 
discussed in greater detail in the next section. Nonetheless, 
what is emerging is the complexity of SphKs isozyme 
and isoform expression pattern, forming the basis of this 
review, and how aberrant expression of these enzymes 
is posing problems in the design and implementation of 
anti-SphK drugs in the clinic. In particular we review 
how aberrant expression of the hSphK1 isoforms can 
confer resistance to SphK1 targeted drugs [25, 26, 102] 
highlighting the challenges faced in anti-SphK drug 
treatment in cancer therapy. 
SPHK/S1P DESIGNER DRUGS
Since SphKs have been recognized as major driver 
proteins in many cancer types, there has been much 
interest in targeting the overexpression of human SphK1 
(hSphK1)/S1P as an anticancer treatment [11, 15, 27, 
48, 57, 60, 239, 269-276]. However, the design of drugs 
to inhibit SphK/S1P action has inherent complexities 
due to the diversity of SphK functions and its important 
role(s) in normal physiology. Thus pan-SphK is not 
considered to be an ideal solution for cancer therapeutic 
targeting. Current strategies in development for cancer 
treatment are targeted towards designer drugs to prevent 
overactivity of S1P action either by selectively targeting 
and blocking S1P receptors [15, 78, 271, 277-279] or 
targeting the S1P producers, SphK1 and/or SphK2 [27, 
108, 275, 280]. Inhibitors of individual or combinations 
of S1PR1-5, to block specific S1PR signaling (Figure 3, 
Table 3), or block SphK1 and/or SphK2 catalyst activity 
are available and listed in Table 2 (adapted from [15, 271, 
281]). There are a number of specific and non-specific 
S1PR modulators currently in clinical use and clinical 
trials for diseases such as multiple sclerosis (primary 
progress and relapse remitting), autoimmune disease, 
inflammatory disorders, kidney transplantation rejection, 
liver and renal disorders, and acute stroke, and these have 
recently been reviewed [281]. Considering anti-SphK 
drugs such as the immunosuppressor prodrug FTY720 are 
being successfully and safely used in the clinic, adds to 
their appeal as anti-cancer therapy. In particular, FTY720 
binding to SphK2 in the nucleus has been shown to inhibit 
the SphK2/histone H3/HDAC 1/2 repressor complex 
therefore allowing the transcription of proteins, such as 
p21, which mediate cell cycle arrest [249].
A number of selective sphingosine-based inhibitors 
and allosteric activators of SphK have been designed to 
combat the hyper-proliferative signaling of cancer and 
other diseases and the value of these compounds are 
reflected in the many filed patents including: Selective 
inhibitors and allosteric activators of sphingosine kinase, 
patent - WO 2014118556 A2; and amidine analogs that 
can inhibit activity of SphK1 and SphK2 patent - WO 
2009146112 A1; long chain base sphingosine kinase 
inhibitors targeting hSphK1 and 2: WO 2013119946 A1, 
reviewed in [282]. 
Inherent problems with SphK/S1P/S1PR designer 
drugs
Targeting SphKs or specific or combinational S1PRs 
for cancer therapy nonetheless has inherent problems. 
Many of the earlier S1P and SphK inhibitors were 
problematic exhibiting non-specific and off-target effects 
and with low potency. As discussed above, individual 
cancer cells express different S1PRs sub-types, and these 
sub-types are associated with cancer development and 
malignancy [123, 139]. For example, as schematically 
shown in Figure 2, most of the S1PR modulators target 
S1PR1 however S1PR1 may not be expressed or be reduced 
in cancer cells. Furthermore, the specific interactors of the 
S1PRs and the location of expression of the S1PRs may 
dictate the cell’s propensity to become malignant. Until 
recently SphK1 has been purported as the main driver 
of non-oncogenic addiction and proliferation. Albeit, 
recently developed compounds such as PF543, which 
inhibits hSphK1 with a greater potency ( > 100-fold) than 
for hSphK2, and the dual inhibitor Amgen 82, which is 
proving to be the most potent dual inhibitor available, 
reduce S1P production, but do not induce cytotoxicity in 
cancer cells at pharmaceutically relevant concentrations, 
undermining their clinical application in cancer therapy 
[27, 276]. As shown in 1483 head and neck cancer cell 
lines tested PF543 failed to increase ceramide, which 
is essential for apoptosis induction [286]. Another 
perceived disadvantage of the SphK1 inhibitor PF543 
was discovered when it was administered to mice and 
exacerbated an inflammatory response [56]. 
Focus is now drawn to inhibition of hSphK2 
and the most studied is the specific SphK2 inhibitor, 
ABC294640 compound [282], now in phase I/II clinical 
trials (Table 4). Compound ABC294640 has been shown 
to effectively suppress proliferation accompanied by a 
decrease in intracellular S1P levels and an increase in 
ceramide [46]. Although this drug has shown significant 
efficacy in cancer cell and animal models, as mentioned 
previously, the specificity of ABC294640 is questionable. 
As Pyne and colleagues discovered ABC294640 induced 
proteosomal degradation of the SphK1a isoform in 
HEK293T and androgen-independent prostate cancer 
cell lines showing ABC294640 was not a specific SphK2 
target (cited in [56]). Second generation SphK2 inhibitors 
such as SLR080811 are even more potent, however, anti-
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intuitively, SLR080811 inhibition of SphK2, increases 
circulating S1P levels significantly, which has potential 
negative consequences as S1P has been shown to drive 
angiogenesis [46, 282]. 
Despite the many drug compounds developed to 
target the SphK pathway, anti-SphK drug design is still 
a challenge due to the functional plasticity of the SphK 
proteins which are activated by phosphorylation, protein 
interactions and the suggestion that their catalytic function 
and regulation may be dependent on conformational 
mobility as reviewed [48]. Also, due to the similarities and 
overlap in the lipid binding pockets of the enzymes in the 
sphingolipid metabolic pathway, achieving high specificity 
is difficult [48]. 
As will be discussed, aberrant expression of SphK1 
isoforms can also affect the efficacy of current cancer 
therapies [25, 26] and may have consequences for anti-
SphK1 and S1P therapy in the presence of comorbid 
conditions [15, 28]. Although progression has been made 
towards understanding the SphK/S1P/S1PR pathways, 
this has also opened a Pandora’s box. As listed in Tables 
2 and 3 a plethora of SphK/S1P/S1PR modulators have 
been developed. Optimistically, a few of these SphK 
modulators are now in Phase I and II clinical trial for 
cancer treatment (Table 4), nonetheless very few of these 
modulators to-date have been approved for clinical use for 
cancer therapy.
DISCOVERY OF SPHK1 ISOFORMS IN 
MOUSE AND HUMANS
There is undisputable evidence to support a 
significant role for aberrant SphK1 and SphK2 isozyme 
expression in cancer development. Despite a huge 
body of basic research and studies on the biochemical 
regulation of the SphK pathways, there has been a delay 
in the introduction of drugs that target SphK function for 
cancer therapy into the clinic. There is now supporting 
evidence to suggest that aberrant expression and/or 
inappropriate cellular localization of SphK1 and SphK2 
isoforms contribute to both oncogenicity and anti-cancer 
treatment resistance. The following sections review the 
characterization of the SphK isoforms and their potential 
oncogenic role and prognostic significance of SphK1 and 
SphK2 isoform expression.
Characterization of the mouse SphK1 isoforms
SphK1 and SphK2 isozymes are both expressed 
as variant isoforms in mice and humans. Murine SphK1 
(mSphK1) was the first mammalian SphK to be cloned 
and shares amino acid sequence homology with the 
corresponding Caenorhabditis elegans (c. elegans), and 
yeast counterparts [23]. Much of the early characterization 
of the mammalian SphK was derived from the mouse 
model. MSphK1 is ubiquitously expressed in many 
different mouse tissues but at differing levels, depending 
on the tissue type [23, 333]. Two similar mSphK1 isoforms, 
mSphK1a and mSphK1b, identified by the Spiegel group, 
were found to differ only at the N-terminal where the 
mSphK1b isoform was identified to be seven amino acids 
longer than the 1a isoform, however showing an actual 
10 amino acid difference overall (Figure 4) [23]. Despite 
the strong sequence similarities the enzymatic traits of the 
two lipid kinases were found to be very different [334]. 
Compared to mSphK1a, mSphK1b was shown to differ 
in cellular location, oligomerization properties and post-
translational modifications [334]. SphK1b was observed to 
be more unstable than the 1a isoform and even though the 
predicted mass of the b- isoform was 43.3kDa, when run 
on SDS-PAGE exhibited an unusually fast mobility and 
the band was detected at 34kDa [334]. This suggested that 
the native conformational structures of the two isoforms 
were vastly different, and the b-isoform has an SDS-
resistant structure. Although the 3 dimensional structures 
of the mSphK isoforms have not been characterized, 
the catalytic domain is adjacent to the N-terminus and 
the proposed conformational differences between the 
isoforms are likely to contribute to the differences in 
enzymatic traits. Although there are only few differences 
in the amino acid sequences of mSPHK1a and mSPHK1b 
[333], the mSphK1a isoforms exhibit 3-fold greater 
activity than the mSphK1b isoform. The mSphK1b 
isoform, which is located predominantly on the plasma 
membrane, was found to be more unstable compared to 
the 1a-isoform and did not accumulate in the cell [334]. 
Treatment with the proteasome inhibitor MG132 slightly 
increased the abundance of the mSphK1a isoform whereas 
the effect on mSphK1b abundance was significantly 
increased, suggesting involvement of the proteasome in 
the differential degradation of the two mSphK1 isoforms 
[334]. Site-directed mutagenesis of unique Cys residues 
in the mSphK1b isoform led to an increase in mSphK1b 
activity and prevented membranous degradation of 
mSphK1b upon addition of proteasome inhibitors 
[334]. Interestingly, mSphK1a was more susceptible to 
degradation when membrane bound suggesting it was 
the ability of isoform binding to the membrane that was 
responsible for mSphK1 protein stability [334]. Structural 
differences were also observed between the -1a and -1b 
isoforms whereby mSphK1b was mainly found as homo-
oligomers and mSphK1a isoforms were mainly observed 
as monomers, allowing a greater diversity of cellular 
function [334]. 
It was only in 2006 that a third murine mSphK1 
isoform, mSphK1a2, was reported [334]. In comparison 
to mSphK1a, the SphK1a2 isoform contains an extra 
valine (Val) residue due to an insertion of three base 
pairs in the coding- region. Thus mSphK1a contains the 
sequence Met-Glu-Pro whereas the mSPHK1a2 isoform 
has the sequence is Met-Glu-Pro-Val revealing a greater 
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similarity between mSphK1a2 and mSphK1b (Figure 
4a). The mSphK1a2 isoform had very similar stability 
and function to its mSphK2 counterpart and was the 
most ubiquitously expressed, followed by mSphK1a and 
mSphK1b in decreasing order of abundance [334]. Much 
of our biological characterization of the SphK isoforms is 
derived from murine models however, although there is 
high amino acid sequence homology between the human 
and mouse SphK proteins at the C-terminal, there are vast 
differences in the N-terminal sequences and apparent 
differences in the ligand binding pockets between the 
different SphK1 isoforms of mammalian species (Figure 
4). Thus, while great inroads to SphK function have 
been acquired through studying the murine models, 
the functionality of hSphK isoforms cannot directly 
be compared to mSphK isoforms due to their profound 
differences at the N-terminal [271]. Here we focus on 
what is known about the human SphK (hSphK) isoforms 
and the further challenges associated with targeting SphK/
S1P as a therapeutic target for multiple diseases. 
Characterization of human SphK1 (hSphK1) 
isoforms
A putative hSphK1 was predicted in 1998 sharing 
sequence homology with c. elegans, yeast and murine 
SphK1 sequences [23], however the hSphK1 was not 
sequenced and characterized until 2000 [206, 335]. 
Due to the high homology in the hSphK1 C-terminal of 
all the mammalian species sequenced, hSphK1 could 
be identified immunohistochemically in human tissue 
using a rabbit polyclonal antibody, thus confirming 
the diversity of hSphK1 expression in different tissue 
types [333]. Using Northern blot analysis, hSphK1 was 
observed to be widely expressed in human tissues with 
highest expression levels in adult liver, kidney, heart and 
skeletal muscle [335]. Since the first discovery of human 
SphK1, three unique isoforms of the hSphK1 have been 
identified to date varying only at the N-terminus: hSphK1a 
(NM_001142601, Q9NYA1); hSphK1b (NM_182965: 
Q9NYA-2) and hSphK1c (NM_021972: Q9AYA1-3), the 
GenbankTM and Uniprot accession numbers, respectively, 
have been provided. Both hSphK1a and hSphK1c are 
similar in size (42.5kDa and 43.9kDa respectively) with 
the 1c-isoform having an additional 14 amino acids at 
the N-terminus (Figure 4b). Both hSphK-1a and -1c 
have similar mobility on SDS PAGE and in some reports 
have been referred to as hSphK1a and hSphK1a+14 to 
distinguish between the two isoforms [25]. The hSphK1b 
(51kDa) isoform contains a unique upstream 86 amino 
acid sequence at the N-terminal region (Figure 4b). It is 
noted that in some reports the hSphK1c isoform refers 
to the longer isoform (470 amino acids) and the hSphKb 
isoform refers to hSphKc (398 amino acids) [53]. For this 
review, the convention will refer to hSphK1b as the 51kDa 
(470 amino acids).
Much of the literature does not specify the human 
SphK1 isoform used in the reported studies, and most 
in vitro studies have conventionally used the shorter 
hSphK1a isoform to determine structure and function 
of hSphK1 in the cell [48]. To-date few reports have 
defined the distribution of the hSphK1 isoforms in cells, 
or in different tissue types, and most studies use stable 
or transient overexpression of the hSphK1 isoforms to 
define their biological significance. Using overexpression 
of hSphK1 isoforms in human cells hSphK -1a and -1b 
isoforms have been demonstrated to have similar S1P 
activity [25, 28, 53] and both isoforms translocate to 
the plasma membrane [25]. However, what is emerging 
is that there are functional differences in the activity of 
the human SphK1 isoforms. Hla and colleagues provide 
evidence showing hSphK1a is preferentially secreted 
from cells and activates extracellular S1P/S1PR1, whereas 
hSphK1b and hSphK1c are more likely to be retained 
in the plasma cell membrane [53]. The suggestion is 
that hSphKa may contribute to the establishment of the 
vascular S1P gradient and vascular integrity under normal 
physiological conditions. As the SphK rheostat is involved 
in inflammation [336], it is possible that hSphK1a has a 
distinct role in inflammatory disease. 
Common and specific interactions of human 
SphK1 isoforms
Studies using the hSphK1b isoform suggest that the 
extra 86 amino acids at the N-terminal may contribute to 
conformational changes relevant to the diversity of SphK1 
function and may impact on efficacy of hSphK1 directed 
drug administration and outcome [15, 57, 271]. As far as 
we are aware, there is only one study to-date that used 
a multiplex-based stable isotope labeling with amino 
acids in cell culture (SILAC) co-immunoprecipitation 
to identify unique and common interacting partners of 
the two major hSphK isoforms (1a and 1b) elucidating 
possible ways by which these interactions may influence 
cancer pathophysiology [28]. Gene ontology analysis 
of the functional roles for the interacting partners of the 
two isoforms showed strong similarities demonstrating 
common functions as expected. Of major interest is the 
difference in the interactions conferred by the unique extra 
86 amino acids of the hSphK1b, which not only allows 
specific binding to the unique upstream N-terminal region 
but also confers conformational differences between 
the two isoforms affecting specific binding affinity. The 
PP2A serine/threonine phosphatase, one of the most well 
characterized hSphK1 partners responsible for deactivating 
SphK bound with greater affinity to the hSphKa (43kDa) 
isoform. As expected, in this study, most of the isoform 
specific interactions were associated with the hSphK1b 
isoform. These interactions included various proteasomal 
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sub-units, and latent-transforming growth factor β-binding 
protein 1. The unique putative proteasomal binding sites 
suggest that this isoform may be more susceptible to 
proteasomal degradation in a breast cancer cell line. This 
observation was supported by a prominent increase in the 
hSphK1b isoform upon treatment with the proteasomal 
inhibitor MG132 whereas hSphK1a protein levels showed 
little change post treatment indicating hSphK1b has a 
higher protein turnover than hSphK1a in cells [28]. 
Although specific functions for each of the SphK1 
isoforms have yet to be identified in vitro and in vivo 
we have some evidence to suggest unravelling the 
individual and common or overlapping functions SphK1 
isoforms will add further complexity to targeting SphK 
in cancer treatment. A full list of the reported SphK1a 
(43kDa) and SphK1b (51kDa) interactors can be found 
in [28]. In these studies by McGowan and colleagues 
the SphK1a (51kDa) and the SphK1b (43kDa) isoforms 
were independently, stably overexpressed. To-date, no 
studies have looked at the likelihood and potential effects 
of hSphK1 heterodimerization (hSphK1a-hSphK1b) and 
their interactors. These types of dimerization studies 
would add to our knowledge of the structural plasticity of 
SphK1, add to the repertoire of protein-interactions, and 
increase our understanding of the extensive downstream 
functions and cellular effects of SphK1 isoforms. As 
recently highlighted by Adams, Pyne and Pyne [48] the 
catalytic function and enzyme regulation through SphK1 
is likely to be dependent on conformational mobility 
and an understanding the dynamic changes in hSphK1 
structure will provide more avenues for the development 
of SphK modulators in targeted cancer therapy.
hSphK1b isoform - a link between diabetes and 
cancer treatments
An important hSphK1b-specific interactor identified 
was the dipeptidyl peptidase 2 (DPP2), which is involved 
in the regulation of glucose metabolism [28]. DPP2/4 
inhibitors block degradation of hSphK1b but have no 
effect on the hSphK1a isoform. As DPP inhibitors are used 
in diabetic treatment, these treatments would increase the 
propensity towards elevated hSphK1b and S1P activity. 
The suggestion that DPP inhibitors may increase cancer 
risk and increased S1P activity has been reported as a 
mediator of oncogenicity: highlighting the “ying and 
yang” of comorbidity treatments (reviewed in [15]).
hSphK1 isoform specific anti-SphK drug efficacy 
Previous studies have shown the involvement of 
the proteasome in the regulation of hSphK1, where novel 
inhibitors of SphK1-S1P activity induced the proteasomal 
degradation of this protein in prostate cancer cell lines 
[266]. Androgen-independent prostate cancer cell lines 
demonstrate higher levels of SphK- 1a and 1b than 
androgen sensitive prostate cells [25, 266]. Further studies 
demonstrated proteasome regulation and degradation of 
hSphK1 was isoform dependent and cell-type specific 
[25, 26, 102]. These studies clearly show that cellular 
phenotypic changes in cell lines also affected proteasomal 
degradation and stabilization of the two major hSphK 
isoforms, which in turn affect anti-SphK drug efficacy. 
As demonstrated in prostate cancer cell lines, hSphK1b 
was less sensitive to proteasomal degradation in androgen-
independent LNCaP-A1 cells compared to LNCaP 
androgen-sensitive cells [25, 26]. The inhibitor of the 
SphK1 and SphK2 isozymes, SKi (2-(p-hydroxyanilino)-
4-(p-chlorophenyl) thiazole)) induced proteosomal 
degradation of hSphK1a and hSphK1b in androgen-
sensitive prostate cancer cells, however failed to promote 
degradation of hSphK1b in androgen-independent prostate 
cancer cells. The apparent inability of the Ski inhibitor to 
affect the hSphK1b expression in androgen-independent 
cells was found to be due to a compensatory increase in 
hSphK1b mRNA expression [25].
Indeed, further studies demonstrated that the 
inhibitor of SphK2, ABC294640 (3-(4-chlorophenyl)-
adamantane-1-carboxylic acid (pyridin- 4-ylmethyl)
amide) was able to reduce the expression of SphK1a in 
androgen-independent LNCaP-AI cells and this was 
prevented by pre-treating these cells with the proteasomal 
inhibitor, MG132 [102]. Overall the major findings from 
these challenging studies are 1) the ubiquitin-proteasomal 
degradation of hSphK1 is important in cell survival, 2) 
differential proteasomal degradation of hSphK1a and 
hSphK1b is cell-phenotype specific, 3) differential 
regulation of hSphK1a and hSphK1b may contribute to 
anti-SphK/S1P therapy resistance as demonstrated in 
prostate cancer cells [25, 26]. 
Although these studies provide some insight into 
the distribution of SphK1 in human tissues and the 
importance of SphK1 in disease, to date there have been 
no explicit studies on the relative expression levels of 
the variant SphK1 isoforms in human tissue, providing 
some open and very pertinent questions that are yet to 
be answered. The caveat of most in vitro studies is the 
reliance on studies of the overexpression of SphK1 in 
stable cell lines and may not truly reflect SphK1 isoform 
expression in normal physiological or tissue samples. It 
is currently unknown whether one or both isoforms are 
expressed in normal cells and whether changes in isoform 
expression levels occur in, or contribute to, disease states 
(i.e. in normal cells and cancer cells and different disease 
states). Determining the relative expression levels of each 
of theSphK1 isoforms may reveal novel roles for the 
two major SphK1 isoforms in cancer and other disease 
development and/or progression. 
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CHARACTERIZATION OF HSPHK2 
ISOFORMS AND THE POTENTIAL OF 
HSPHK2B AS AN ONCOTARGET
The SphK2 isozyme is gaining much prominence 
as a cancer therapeutic target and may prove to have 
greater efficacy as an oncotarget than its comparative 
isozyme hSphK1, which is driving the development of 
the hSphK2 inhibitors (Table 2), and the ongoing clinical 
trials of the hSphK2 ABC294640 (Table 4). However, 
we know little about the structure and function of SphK2 
and even less regarding the hSphK2 isoforms. The 
SphK2a genes were cloned in both murine and humans 
in 2000 and the comparison is shown in Figure 6 [16]. 
Interestingly, the SphK2b isoform is not expressed in the 
mouse therefore functional isoform-specific studies have 
been limited to cell lines [337]. The SphK2 encodes at 
least 4 predicted variants [a-d] however 5 isoforms have 
been annotated: isoform 1 ‘a’ (NM_020126; Q9NRA0-1); 
isoform 2 ‘b’ (NM_001204158.2; Q9NRA0-2); isoform 
3 ‘a’ (NM_001204159.2; Q9NRA0-3); isoform 4 ‘c’ 
(NM_001204160.2; Q9NRA0-4); and isoform 5 ‘d’ 
(NM_001243876.1; Q9NRA0-5); the GenbankTM and the 
Uniprot accession numbers, respectively, are provided. 
Note: transcripts for isoform 1 and 3 encode the same 
isoform ‘a’. Comparison of SphK2a-d is illustrated in 
Figure 6. 
The hSphK2a and -b isoforms have been confirmed 
with the b-isoform containing 36 extra amino acids at 
the N-terminal, the c and d isoforms are predicted [46]. 
The hSphK2-a, b and c isoforms contain five conserved 
catalytic regions (nominated C1-C5) whereas SphK2d 
does not possess two of these catalytic regions (C4-C5) 
and therefore is most probably inactive [46]. Original 
studies in human cell lines refer to the longer isoform 
(b-isoform), containing the additional 36 amino acids 
at the N-terminus, as hSphK2-L and the short isoform 
(a-isoform) as hSphK2-S [337]. Firstly, the longer isoform 
was found to be predominant in the human cell lines tested 
and secondly, these studies defined distinct differences 
in the physiological role of the N-terminal extension of 
hSphK2. To-date hSphK2 isoforms have been reported to 
differ in their subcellular localization with isoform 1 ‘a’ 
located in the cytoplasm and the membrane, and isoform 
2 ‘b’ reported to be located at the lysosome membrane 
{reference: ncbi.nim.nih.gov;gene:56848]. Billich and 
colleagues presented data showing that hSphK2-L 
was involved in the regulation of cell proliferation and 
apoptosis in serum deprivation and this was cell-type 
dependent [337]. 
Based on kinetic studies, the N-terminal extension 
of the human SphK2b (hSphK2-L) has been reported to 
be responsible for more efficient binding to FTY720, a 
sphingosine analog, with more effective activation than 
the shorter isoforms [248]. This observation is interesting 
due to the use of FTY720 currently in the clinic for 
multiple sclerosis and its promise in cancer therapy. 
Hence, SphK2b may prove to be a more effective anti-
cancer target in vivo. Work to characterize the functions 
of the known isoforms is an ongoing requirement for our 
understanding of the cellular roles of these isoforms and 
their contribution to disease states and the existence of 
additional SphK2 variants remains a possibility.
SPHK/S1PRS AS DIAGNOSTIC OR 
THERAPEUTIC MOLECULAR 
BIOMARKERS IN CANCER
Given the considerable evidence showing increased 
SphK1/S1P/S1PRs is present in many types of cancer, as 
discussed in this review and others [98, 223, 338, 339], 
there is the potential for SphK isozymes, isoforms and 
S1P and S1PRs as potential new biomarkers for clinical 
diagnosis and prognosis, for early cancer detection, as 
an indicator of progression and tumor aggressiveness. 
Prime examples include breast, cervical, prostate, head 
and neck, and brain cancers. Overexpression of SphK1 
and differential S1PRs distribution are associated with 
poor prognosis and disease stage in breast cancer and may 
prove to be strong candidates as diagnostic and prognositic 
markers for ER+ and ER- breast cancers, endocrine 
resistance, and metastasis [11, 230, 340]. In cervical 
cancer SphK1 was significantly increased in comparison 
to normal tissues and patients had a higher probability 
of recurrence and lower overall survival [130]. Likewise 
overexpression of SphK1 is found in aggressive gliomas 
and is associated with poor survival [341]. 
Nevertheless, SphK1 overexpression is not an 
indicator for all cancers. Measurement of SphK/S1P 
and S1PR levels as a cancer diagnostic marker has to be 
carefully considered as biomarkers as overexpression is 
not necessarily related to poorer prognosis. In prostate 
cancer decreased levels of circulating S1P was reported 
during prostate cancer progression potentially stemming 
from a significant decrease in erythrocyte SphK1 levels, 
and this S1P decrease correlates with high prostate specific 
antigen (PSA) levels, lymph node status and may be an 
early marker for androgen independent tumors [339]. 
As discussed above, SphK2 is also gaining ground as a 
marker of cancer progression [107, 220]. 
In summary, although SphK1 is highly expressed 
in many cancer cell types, compared to its contemporary 
cell type, its suitability as a diagnostic or therapeutic 
biomarker for all cancers is still unknown. For some cell 
types it may be an indicator of cancer development and of 
resistance to conventional cancer therapies. As highlighted 
in this review, aberrant SphK isozyme and isoform 
expression levels and cellular localization, differential 
S1PR1-5 expression, and intracellular and extracellular 
S1P levels are all associated with cancer initiation, 
development, progression and metastasis. Further profiling 
and characterization of the SphK pathway will provide a 
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more detailed analysis for future diagnosis and prognosis 
in the various cancer-types. The feasibility and complexity 
of developing a method to detect SphK/S1P/S1PRs as 
biomarkers in the clinical samples, such as blood samples, 
is another consideration in the future. 
KEY ISSUES AND FUTURE 
CHALLENGES FOR SPHK AS AN 
ONCOTARGET
Disruption of the SphK rheostat is now well 
recognized as a hallmark of cancer development and an 
instigator of cancer treatment resistance. Nonetheless, 
SphK balance of sphingosine to S1P is necessary for 
normal cell physiology so ablating the function of SphK 
has clinical concerns for deleterious off-target effects. 
In this review we have provided an overview of 
the promise, and the problems, of targeting SphKs, S1P 
and S1PRs as novel cancer treatments and outlined the 
approach of pharmacologically targeting SphK1 and/or 
SphK2 to alter their activity so that clinically beneficial 
changes in cancer patients can be achieved. In the absence 
of mutations in SphK and S1PRs it has been difficult 
to determine the extent of their involvement in cancer 
and non-oncogenic addiction has been proposed as the 
mechanism driving SphK-associated malignancy. Hence, 
the term drugging the addict(s) (SphK1, SphK2 and 
S1PRs) has been the driving force for novel cancer drug 
design. As listed in Tables 2 and 3 there is no paucity to 
the growing list of anti-SphK, anti-S1P, and anti-S1PRs 
modulators, of which some are in clinical trials, Table 
4. While SphK/S1PR modulators hold much promise 
as additional novel cancer therapies, as indicated in 
this review, there are still many challenges facing anti-
SphK drug use in cancer therapy. Although SphK1 has 
historically been described as a pro-proliferative lipid 
enzyme, whereas SphK2 has been described for its pro-
apoptotic effects, in practice inhibitors of SphK1 have 
failed to induce apoptosis whilst the hSphK2 inhibitors, 
ABC294640 and FTY720, are proving to be more 
efficacious inhibitors of cell proliferation. Interestingly, 
the observation that FTY720 binds more efficiently to 
the unique N-terminal of the SphK2b isoform suggests 
that the unique SphK2 N-terminal domain may be a more 
attractive oncotarget such that isoform-specific inhibitors 
can be designed. Nevertheless, inhibition of SphK2 by 
some SphK2 inhibitors demonstrated increase in S1P 
production, and the physiological consequences of this 
increase are unknown. Adding to the complexity of SphKs 
role in cancer, aberrant SphK isozyme localization has 
been cited as potentially contributing to carcinogenesis. 
Although much insight has been gained from studying 
SphK isozymes and isoforms in mouse models there are 
inherent major differences between human and mouse 
SphK isoforms. More recent attention has been focused on 
the human SphK isoforms, especially since the discovery 
that androgen independent prostate cancer cells expressing 
hSphK1b isoform are refractory to SphK1 inhibitors. Very 
little is known of the physiology and mechanism of SphK 
isoforms in culture and clinical samples, such as if one or 
both isoforms are present in cells and if the physiology of 
enzymatic regulation is dependent on the dynamic changes 
in isoform expression and interactions. Understanding the 
structural conformational plasticity of SphK1 isoforms 
through homo- and hetero- dimerization and how this 
relates to normal function and disease will provide more 
options for SphK oncotarget potential.
In conclusion, although there is great excitement 
in developing SphK/S1P/S1PR modulators for cancer 
treatment the intricacies of the SphK pathways are still 
being unraveled. New knowledge gained from the study 
of the human SphK isozymes, and in particular human 
SphK isoforms biology, will provide more understanding 
of SphKs role in cancer progression, metastasis, and drug 
resistance, allowing for the development of more specific 
and effective anti-SphK oncotargets. 
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